FDA Approves Eisai, Biogen's LEQEMBI Injection for Early Alzheimer's
() -- The US Food and Drug Administration has approved Eisai (TYO:4523) and Nasdaq-listed Biogen's supplemental Biologics License Application for LEQEMBI IQLIK, a once-weekly subcutaneous injection administered via autoinjector for early Alzheimer's disease. The new formulation is an at-home alternative to intravenous